ABBOTINDIA

🚀 Business Highlights

📊 Financial Performance Abbott India posted strong growth in FY25 with revenue crossing ₹6,400 crore and net profit rising around 18% year-on-year. In Q4 FY25, profit jumped nearly 28% to about ₹367 crore, supported by double-digit revenue growth. The company announced a hefty final dividend of ₹475 per share, reflecting strong cash flows and confidence in future performance. 🚀 Business Highlights Growth has been driven by its core therapy areas such as diabetes care, thyroid treatments, gastrointestinal medicines, and anti-infectives. The company signed a non-exclusive license to market Vonoprazan, a drug used for acid reflux, under the brand name Vonefi in India. Abbott has been expanding its diagnostic and device portfolio with launches like FreeStyle Libre continuous glucose monitoring systems and advanced cardiac care devices. Strong demand across chronic therapies continues to support steady sales momentum. 📈 Market Sentiment The stock has been performing well on the back of robust earnings and consistent dividend payouts. Brokerages remain positive due to its strong brand recall, leadership in multiple therapy areas, and healthy balance sheet.